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Introduction
Extended-spectrum beta-lactamase (ESBL) producing strains of Gram-negative bacilli are on the rise and present a major threat especially in India. Urinary tract infection (UTI) is one of the most common bacterial infections encountered as both hospital-and community-acquired infections. [1] The course and outcome of an infection is affected with the limited therapeutic options available. [2] Uropathogens differ in terms of the virulence factors and pathogenic mechanisms that allow them to colonize and infect the urinary tract leading to hospital and community acquired infections. [3] To the best of our knowledge, only few studies exist in India on the evaluation of E-test along with Polymerase Chain Reaction (PCR) assay in Nadagopal, et al 
Polymerase chain reaction
The plasmid DNA was extracted from the ESBL-producing Escherichia coli isolates using plasmid mini kit (HiYield plasmid mini kit, Real Biotech Corporation, Banqiao, Taiwan). The extracted Plasmid DNA was stored at -20°C until use.
All the plasmid DNA samples were subjected to uniplex PCR using primer sets each specific for TEM, SHV and CTX-M genes (George et al. In Press). The PCRs were carried out in an Eppendorf thermal cycler (Mastercycler ® personal 5332, Hamburg, Germany). Negative controls replacing the template with nuclease free water were included in every assay. An aliquot of 5 µL amplicon was analyzed by gel electrophoresis: TEM-1080 bp, SHV-471 bp and CTX-M-544 bp. Statistical analysis was carried out using Epi Info 7.1.2.
Results
Information on patients in relation to age and length of hospitalization (in-patients) is shown in [ Table 1 ]. Among the 100 isolates, 64 (64%) isolated from 62 patients were positive for ESBL, majority were E. coli. The age of the patients (n = 92) ranged from 1 year to 89 years and the median was 54.5. Among the patients, 27 were females and 65 were males; the difference in ESBL-positive status between them was not statistically significant (χ 2 = 1.88, P = 0.17). Out of 92 patients, 40 were inpatients and 52 were outpatients. The difference in ESBL-positive rate of the strains between them was not significant (χ 2 = 0.18, P = 0.67).
Among the inpatients, four were from high dependency units (ICU and CCU), of which three were positive for ESBL by E-test and PCR. Clinical information of the patients with uropathogens in mid-stream urine samples was shown in [ Table 2 ]. The ESBL-positive strains were also found resistant to other antimicrobials tested and this includes ciprofloxacin (n = 57), gentamicin (n = 41), cefoperazone-sulbactum (n = 6) and nitrofurantoin (n = 12). Among the antimicrobials tested, ESBL-producing strains showed highest susceptibility (9.68%) to cefoperazone-sulbactum. The 64 phenotypically ESBL-positive strains were further tested by E-test ESBL strips for confirmation and by uniplex PCR using primers specific to CTX-M, TEM and SHV genes.
Among 64 strains tested, 55 (85.9%) were E. coli, 4 (6.2%) were Enterobacter spp., 3 (4.7%) were Klebsiella spp. and one each of Proteus mirabilis (1.6%) and Pseudomonas aeruginosa (1.6%). With E-test ESBL strips, 59 (92.2%) were positive for ESBL. PCR results indicated positive for CTX-M in 60 (93.7%) strains followed by TEM in 15 (23.4%) and SHV in 3 (4.7%) strains. Two (3.1%) strains (one E. coli and one Enterobacter spp.) were positive for all the three genes, 13 (20.3%) strains were positive for both TEM and CTX-M genes. In all, 62 (96.9%) strains were positive for any of the three gene targets tested. Among the five E-test negative strains, 3 were positive by PCR for CTX-M, one positive for TEM and the other was negative by PCR as well. There was no statistically significant difference in the findings of E-test and PCR testing in the determination of ESBL producers (Fisher exact test -two-tailed P = 0.15). The kappa coefficient between the two test was 0.252; the chance expected agreement and the observed agreement were 0.89 and 0.92 (SE = 0.11; z = 2.26; P = 0.01), respectively. The confidence interval (95%) ranged between -0.189-0.694, and the strength of agreement was considered to be 'fair'.
Discussion
Sixty-four strains were positive for ESBL on screening with ceftazidime and ceftazidime-clavulanic acid by Double Disk Synergy test. Majority of the patients (33.7%) presented with UTI alone (no underlying abnormalities); of these, 87.1% were positive for ESBL-producing strains. This was followed by urethretic/ureteric/prostate-related abnormalities, Urethral/ureteric/renal calculi and diabetes as underlying complications. With E-test ESBL strips, 59 (92.2%) were positive for ESBL. PCR results indicated CTX-M in 96.8% of the strains followed by TEM in 24.2% and SHV in 4.8% of the strains. Two (3.22%) strains were positive for all the three genes; 13 (21%) strains were positive for both TEM and CTX-M genes. In PCR, all 62 (96.87%) strains were positive for any of the three gene targets tested.
To the best of our knowledge, only a few studies exist in India on the evaluation of E-test along with PCR assay in the detection of ESBL producers. Using E-test to detect the presence of ESBL resulted in a false-positive outcome in 14% of the cases resulting in unnecessary isolation of patients (barrier nursing) that could have been omitted by using a genotypic method. Our study demonstrates the usefulness of E-test because it detected almost all ESBL positives compared to PCR outcome. Kaur and Aggarwal [5] reported 59% of their E. coli strains as possessing CTX-M genes. Many of the Klebsiella isolates were positive for 2 or all 3 genes. In our study, CTX-M was positive in 98.2% (54/55) of E. coli strains. TEM was positive in 15 strains including 12 E. coli, 2 Klebsiella and 1 Enterobacter spp. Occurrence of SHV was low (4.7%) and found in two Enterobacter spp. and an E. coli strain. Two of these SHV positive strains co-occurred with CTX-M and the other strain was positive for all three genes tested. Manoharan et al. [6] reported TEM and CTX-M to be predominant in E. coli (39.2%) while, among the Klebsiella spp., TEM, SHV and CTX-M occurred together in 42.6% of the isolates.
Among our in-patients, out of four E. coli strains recovered from high dependency units (ICU and CCU), three were ESBL positive. This indicates the need of intense surveillance among critical care patients and institution of appropriate measures to contain the spread of resistant pathogens causing hospital-acquired infections.
Compared with the DDST, the inhibitory potentiated disk diffusion and E-strip tests were found to be preferable methods for detecting ESBLs, with better sensitivity (100%) and specificity (97.6%) and positive predictive values (97.3%).
The British Society of Antimicrobial Chemotherapy (http://bsac.org.uk/) and the Health Protection Agency of the United Kingdom (http://www.hpa.org.uk/) suggest testing all isolates of E. coli or Klebsiella spp. with ceftazidime (the best indicator for TEM and SHV-derived ESBLs) and cefotaxime (the best indicator for CTX-M types) or with cefpodoxime (a good indicator for all ESBL types) as a first screening test. Giriyapur et al. [7] showed ceftazidime to have a better sensitivity and specificity as a screening agent for efficient detection. In our study, only ceftazidime disks were used both for screening by DDST and E-test.
Conclusions
Using E-test ESBL strips, 92.2% were found positive for ESBL. PCR results indicated a majority to be positive for CTX-M (93.7%) followed by TEM (23.4%) and SHV (4.7%). In all, 62 (96.9%) strains were positive for any of the three gene targets tested. There was no statistically significant difference in the findings of E-test and PCR testing. Any one of these methods may be used to verify the findings of disk diffusion test. Monitoring for ESBL producing strains of coliform bacteria would reveal information on the magnitude of the problem and is important to rationalize the antibiotic policy to be followed in the country.
